Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ABUS 
Arbutus Biopharma Corp (ABUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/15/2025: ABUS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.34
1 Year Target Price $5.34
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.98% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 620.55M USD | Price to earnings Ratio - | 1Y Target Price 5.34 |
Price to earnings Ratio - | 1Y Target Price 5.34 | ||
Volume (30-day avg) 4 | Beta 1.24 | 52 Weeks Range 2.71 - 4.72 | Updated Date 07/15/2025 |
52 Weeks Range 2.71 - 4.72 | Updated Date 07/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -738.49% |
Management Effectiveness
Return on Assets (TTM) -31.58% | Return on Equity (TTM) -79.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 509029897 | Price to Sales(TTM) 96.92 |
Enterprise Value 509029897 | Price to Sales(TTM) 96.92 | ||
Enterprise Value to Revenue 79.5 | Enterprise Value to EBITDA -5.64 | Shares Outstanding 191527008 | Shares Floating 136355824 |
Shares Outstanding 191527008 | Shares Floating 136355824 | ||
Percent Insiders 21.89 | Percent Institutions 59.38 |
Upturn AI SWOT
Arbutus Biopharma Corp
Company Overview
History and Background
Arbutus Biopharma Corp. (ABUS) was founded in 2007 (originally Tekmira Pharmaceuticals). It is a biopharmaceutical company focused on developing novel therapeutics for chronic hepatitis B virus (HBV) infection.
Core Business Areas
- HBV Therapeutics: Development of therapies to cure chronic HBV infection, including RNAi therapeutics, capsid inhibitors, and other approaches.
Leadership and Structure
William Collier is the President and CEO. The company has a typical organizational structure for a biopharmaceutical company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- AB-729 (RNAi Therapeutic): AB-729 is Arbutus's most advanced product candidate, an RNAi therapeutic designed to reduce hepatitis B surface antigen (HBsAg). It is currently in clinical development. There is no current market share but potential competitors include Assembly Biosciences, Arrowhead Pharmaceuticals, and Vir Biotechnology.
- AB-101 (Capsid Inhibitor): AB-101 is an oral HBV capsid inhibitor, designed to disrupt HBV core protein assembly and viral replication. Currently in development. Competitors include Assembly Biosciences and other companies developing similar capsid inhibitors.
Market Dynamics
Industry Overview
The HBV therapeutics market is large and growing, driven by the high prevalence of chronic HBV infection worldwide. There is a significant unmet need for curative therapies.
Positioning
Arbutus is positioned as a key player in the HBV cure space, with a focus on developing novel RNAi and capsid inhibitor therapies. Competitive advantages include their intellectual property and clinical trial data.
Total Addressable Market (TAM)
The global hepatitis B therapeutics market is projected to reach billions of dollars. Arbutus is aiming to capture a significant share of this market by developing curative therapies.
Upturn SWOT Analysis
Strengths
- Strong intellectual property portfolio
- Experienced management team
- Promising clinical trial data for AB-729
- Focus on a significant unmet medical need
Weaknesses
- Dependence on clinical trial success
- High cash burn rate
- Limited revenue generation
- Subject to regulatory risks
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of HBV pipeline
- Successful commercialization of AB-729
- Acquisition or licensing of new technologies
Threats
- Clinical trial failures
- Competition from other HBV therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- VIR
- GILD
- JNJ
Competitive Landscape
Arbutus is among multiple companies seeking a cure for Hepatitis B, with each employing slightly different tactics. Arbutus has an advantage with their intellectual property and ongoing clinical trials, but is a much smaller company that the other competitors in the market.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been based on R&D advancements, securing grants, and entering into collaboration agreements.
Future Projections: Future growth is dependent on the success of AB-729 and other pipeline products in clinical trials and eventual regulatory approval. Analyst projections vary based on perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing AB-729 into Phase 3 clinical trials, developing next-generation capsid inhibitors, and exploring new HBV targets.
Summary
Arbutus Biopharma is a development-stage biopharmaceutical company focused on curing HBV infection. The company's valuation hinges on the success of its pipeline, primarily AB-729. Clinical trial results will be a critical determinant of its success. Arbutus is dependent on external funding, partnerships and is susceptible to competition from larger, well established companies. It needs to show positive clinical outcomes and partnerships to survive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arbutus Biopharma Corp
Exchange NASDAQ | Headquaters Warminster, PA, United States | ||
IPO Launch date 2015-08-03 | President, CEO & Chairman Ms. Lindsay Androski J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.arbutusbio.com |
Full time employees 44 | Website https://www.arbutusbio.com | ||
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.